Track topics on Twitter Track topics that are important to you
Cranial electrotherapy stimulation(CES) is a noninvasive procedure that has been used for decades in the United States to treat anxiety, depression, and insomnia in the general population. Whether CES is an effective treatment for patients with a DSM-IV diagnosis of generalized anxiety disorder (GAD) has not previously been explored. The goal of this study was is to evaluate the efficacy of CES in alleviating anxiety in patients with DSMIV-diagnosed GAD. Specifically our hypothesis was that CES would demonstrate possible efficacy in reducing symptoms associated with GAD from baseline to end of trial, as determined by: (1) change from baseline in the Hamilton Anxiety Scale (HAM-A) total score. a.) the proportion of responders (much or very much improved) as assessed by the CGI Improvement ratings by visit b.) the proportion of responders (50% reduction from total HAM A baseline score) according to the HAM A scores by visit c.) the proportion of patients in remission (HAM A score ≤7) by visit
This study utilized a 6-week open-label design to test CES in the treatment of GAD. The study was funded by Saban Family foundation. The devises were provided by Electromedical Products Inc. (EPI) which is a technology company manufacturing the cranial stimulators. This company has no relationship with any of the investigators of the study. There are no explicit or implicit conflicts of interest. Participants were recruited from August 2005 to March 2006 from the UCLA Anxiety Disorders Program at the Semel Institute for Human Behavior. Permission from UCLA's Institutional Review Board was obtained to conduct this study. All eligible subjects provided approved written consent prior to the initiation of any study related procedure.
Patient Selection: Male or female outpatients aged 18 to 64 years were eligible if they had a current diagnosis of GAD. At screening, GAD diagnosis was confirmed by conducting the MINI interview.(Sheehan, Lecrubier et al. 1998) Patients had to have a score ≥ 16 on the Hamilton Anxiety Rating Scale (HARS) and < 17 on the 17-Item Hamilton Depression Rating Scale (HDRS) at baseline to be considered for enrollment.(Hamilton 1959; Hamilton 1960) Lower then usual HARS were permitted to include milder cases of GAD. Patients were excluded if they had a primary diagnosis meeting DSM-IV criteria for any other Axis I disorder other than GAD, as were patients who met DSM-IV criteria for mental retardation, any pervasive developmental disorder or neurological impairment. Also excluded were those with a recent (6 months) history or current diagnosis of drug or alcohol dependence or abuse, current suicidal ideation and/or history of suicide attempt or any personality disorder of sufficient severity to interfere with participation in the study. Other exclusion criteria included a history or presence of a medical disease that might compromise the study or be detrimental to the patient. Women who were pregnant or breastfeeding and women of childbearing potential who were not practicing a reliable form of contraception were also excluded from the study and the use of any psychotropic medication. Patients were permitted to be on a stable, therapeutic dose of SSRI or SNRI if they were taking their medications for at least 3 month and were still symptomatic after at least 3 months of treatment. Patients who used PRN as-needed benzodiazepines were permitted to enter the study if their use of the medications did not exceed two times per week. Women who were pregnant or breastfeeding and women of childbearing potential who were not practicing a reliable form of contraception were also excluded from the study. Study visits were conducted at baseline and at the end of 3 and 6 weeks of treatment. Patients who met all of the eligibility criteria at baseline were enrolled and administered CES treatment.
Results: Fifteen subjects expressed interest in the study and engaged in an initial telephone screen. Eight percent (n=3) of participants were deemed ineligible to participate. Reasons for ineligibility included age (n=1; 3%) and psychiatric co morbidity (n=2; 6%). Twelve subjects enrolled and received CES treatment. The mean age of the sample was 42.83±10.7 years. Of the twelve individuals enrolled in the study 9 (75%) were female and 3 (25%) were male. Five participants (41.6%) had been taking psychotropic medications for at least 3 months prior to enrollment and continued throughout the study; two participants took venlaflaxine and the remaining 3 patients took benzodiazepines on an as-needed basis no more than twice a week (2 took alprazolam, and 1 took lorazepam). Overall, 75% of patients (n=9) completed the study. Three subjects discontinued after baseline due to adverse events, including dizziness (n=2) and headache (n=1). A significant change (11.5 points) was found from baseline to endpoint in HARS scores (t= 8.59 p= 0.001). The mean change from baseline was significant after 2 weeks of treatment and continued to increase over time. At endpoint, 6 (66%) of 9 patients had a 50% decrease on HARS and a score of 1 or 2 on CGI improvement, and were considered responders to treatment. An additional patient improved but did not meet criteria for response. Mean HDRS score changed from 10.5±15.01 at baseline to 6±3.64 at endpoint (t= 3.01, p=0.01). A significant change was also found from baseline (30.3±11.49) to endpoint (23.3±6.76) in UCLA 4D Anxiety Subscale scores (t=2.63, p= 0.03).
Results of the current study demonstrate a significant improvement with CES, with a decrease in HARS score similar to that found in clinical trials with antidepressant and anxiolytic medications .(Katz, Reynolds et al. 2002; Rickels and Rynn 2002; Pollack, Meoni et al. 2003; Sheehan and Mao 2003; Bielski, Bose et al. 2005; Brawman-Mintzer, Knapp et al. 2006; Dhillon, Scott et al. 2006). The effect size is 2.4 appears to be very large. However, it is expected in an open trial where some part of the parts of the effect could be due to placebo response. The above cited studies had an effect size for placebo ranging from 0.74 to approximately 1.72. Most of the recent pharmacological studies in GAD observed a large placebo response which makes it imperative to conduct placebo-controlled or sham-controlled study to fully evaluate the treatment effect in this population (Rickels and Rynn 2002)
The patients generally liked the treatment and 3 of them continued to use the devise after the experiment was over and purchased their own CES stimulator. However, 3 of the subject experience the side effects which caused them to withdraw prematurely from the study. Presence of side effects in some of the patients could be the sign of some physiological effect in these patients which needs to be studied in future studies.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Generalized Anxiety Disorder
Cranial electrotherapy stimulation (CES)
University of California, Los Angeles
Published on BioPortfolio: 2014-07-24T14:20:12-0400
The investigators are investigating new indications of Transcranial Magnetic Stimulation (TMS) by conducting a pilot randomized-controlled trial (RCT) comparing structural neuronavigation-...
Generalized Anxiety Disorder (GAD) has high prelevance (up to 8.5%; Roy-Byrne & Wagner, 2004) and leads to functional impairment (Wittchen et al., 2002; Ballenger et al., 2001). Researcher...
This clinical trial is an investigator-initiated open label study designed to evaluate the safety and efficacy of sTMS in subjects with Generalized Anxiety Disorder.
The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD)
Generalized anxiety disorder (GAD) is poorly understood compared with other anxiety disorders, and debates persist about the seriousness of this disorder. Few data exist on GAD outside a small number ...
The Generalized Anxiety Disorder Scales GAD-7 and GAD-2 are instruments for the assessment of anxiety. The aims of this study are to test psychometric properties of these questionnaires, to provide no...
This is a feasibility study evaluating the safety, tolerability, and potential anxiolytic efficacy of the α2 agonist guanfacine extended-release (GXR) in children and adolescents with generalized anx...
Although generalized anxiety disorder (GAD) is common and disabling, there are few Canadian studies on this mental illness. We compared the characteristics, health status, health services use and heal...
Generalized anxiety disorder (GAD) is a persistent anxiety disorder with a high rate of relapse. While several trials have demonstrated the efficacy of pharmacotherapy for GAD treatment, fewer studies...
Anxiety disorder characterized by the persistent and irrational fear, anxiety, or avoidance of social or performance situations.
Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. Some are also effective as anticonvulsants, muscle relaxants, or anesthesia adjuvants. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.
A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
Stimulation of the brain, which is self-administered. The stimulation may result in negative or positive reinforcement.
Psychiatry is the study of mental disorders and their diagnosis, management and prevention. Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...
Sleep disorders disrupt sleep during the night, or cause sleepiness during the day, caused by physiological or psychological factors. The common ones include snoring and sleep apnea, insomnia, parasomnias, sleep paralysis, restless legs syndrome, circa...